The FDA cleared Roivant’s brepocitinib, marketed as Lisraya, for adults with dermatomyositis—marking a major regulatory step for the company’s once-daily, oral inhibitor approach. The decision follows FDA reviews of the therapy licensed and developed under Roivant’s Priovant subsidiary. Clinicians currently rely largely on high-dose steroids and other immune-suppressing regimens, creating room for a targeted oral option in a rare, chronic autoimmune population. Roivant positioned the approval as its first major regulatory win in the dermatomyositis indication, with broader development plans tied to other rare immune diseases. For the market, the decision adds a new branded therapy to the rare inflammatory landscape and underscores the ongoing shift toward JAK1/TYK2-targeted pills in diseases with limited oral alternatives.